Generally, the efficacy of anti-PD-1 antibody is believed to depend on the tumor microenvironment with PD-ligand 1 (PD-L1) expression in cancer cells and the presence of tumor-infiltrating lymphocytes (TILs), mediating adaptive immune resistance [23]. The gene discussed is CD274; the disease is neoplasm.